Mouse embryos lacking the Runx1 transcription factor exhibit an angiogenic defect accompanied by the absence of hematopoietic stem cells (HSCs). To ask whether Runx1 plays a direct role in angiogenesis, we established a novel endothelial progenitor cell line, designated AEL-DR1, from the aorta-gonad-mesonephros (AGM) region of Runx1-null mouse. We introduced Runx1 cDNA into AEL-DR1 cells under the doxycycline-inducible promoter. The ability of AEL-DR1 cells to form vascular networks on matrigel was highly enhanced by the restored expression of Runx1. By molecular comparison of mRNAs in AEL-DR1 cells before and after the induction of Runx1, we found that mRNA expression of insulin-like growth factor-binding protein 3 (IGFBP-3) is downregulated by Runx1. Gel retardation and reporter assays revealed that Runx1 binds to the promoter region of mouse IGFBP-3 gene and represses its transcription. When IGFBP-3 was exogenously added in the matrigel assay, the angiogenesis-enhancing activity of Runx1 was suppressed in a dose-dependent manner. These results demonstrate that Runx1 is directly involved in angiogenesis by repression of IGFBP-3 mRNA expression.
Introduction
Runx1 (also known as AML1, CBFa2, or PEBP2aB) is a member of the Runt-related transcription factors (Miyoshi et al., 1991; Meyers et al., 1993; Ogawa et al., 1993; Wang et al., 1993) . The Runx proteins (Runx1, 2, and 3) recognize a specific DNA sequence and activate or repress the transcription of several genes along with their heterodimeric partner protein CBFb (for review, see Speck and Gilliland, 2002) . Homozygous disruption of the Runx1 or CBFb gene in mice resulted in embryonic lethality around 12.5 days post coitum (dpc) due to severe defects in hematopoiesis (Okuda et al., 1996; Wang et al., 1996) . In addition, vascular systems in yolk sac, heart, and head of the Runx1-null embryo were defective in the development of branched small vessels from arteries. An elegant study by Takakura et al. (2000) demonstrated that the impairment of angiogenesis in the Runx1 knockout mouse embryo is caused by a poor supply of angiopoietin-1 from hematopoietic stem cells (HSCs). In vitro proliferation of the Runx1-deficient endothelial progenitor cells occurred normally in the primary culture of the AGM region (Mukouyama et al., 2000) . However, angiogenic capacity of the Runx1-deficient endothelial cells has not been evaluated.
The knockin mice whose Runx1 locus is replaced with the LacZ gene revealed that some aortic endothelial cells in the AGM region and the vitelline/umbilical arteries are positive for Runx1 (North et al., 1999) . Previous reports suggested that Runx1 and/or Runx2 (also named as AML3, CBFa1, or PEBP2aA) are expressed in several endothelial cell lines of human, bovine, and mouse origin (Namba et al., 2000; Sun et al., 2001) . Recently, it has been shown that expression of Runx2 in rat aortaderived cells stimulated vascular sprouts (Sun et al., 2004) , while the introduction of the dominant-negative form of Runx2 in the human endothelial HBME-1 cells was inhibitory to their migration, invasion, and vascular tube formation on matrigel (Sun et al., 2001) . Moreover, Runx2 has been shown to be a critical regulator of the mRNA expression of vascular endothelial growth factor (VEGF) (Zelzer et al., 2001) . These data demonstrated that Runx2 could modulate angiogenic properties of adult endothelial cells. In addition, expression of the CBFb-MYH11 fusion protein in the mouse endothelial cell line MSS31 inhibited proliferation, migration, and the expression of angiopoietin-1 in the cells (Namba et al., 2000) and since the fusion protein is known to interfere with the biological activities of Runx1, these experiments support a functional role for Runx1 in angiogenesis. However, using developing mouse embryos or in vitro differentiated ES cells, it has been difficult to investigate the angiogenic properties of Runx1-deficient endothelial cells independently of hematopoietic cells.
In this study, we overcame this problem by immortalizing endothelial progenitor cells originating from the AGM region of Runx1-deficient mouse embryos and established a conditional Runx1 expression system in this cell line. In this new cell line, inducible expression of Runx1 conferred an improved vascular network formation capacity. Moreover, we found that enforced expression of Runx1 suppresses the production of IGFBP-3 in the endothelial progenitor cell line. As IGFBP-3 inhibited in vitro angiogenesis, we propose that Runx-1 is a gatekeeper for embryonic angiogenesis via regulation of the IGFBP-3 gene.
Results

Establishment of endothelial progenitor cell lines from the Runx1-null AGM region
To investigate the function of Runx1 in angiogenesis, we attempted to immortalize the endothelial progenitor cells grown during primary culture of the AGM region of Runx1-null mouse embryos (Mukouyama et al., 2000) . When we infected the proliferating AGM-derived cells in the early days of the primary culture with a retrovirus encoding a temperature-sensitive mutant of the SV40 large T antigen (Lee et al., 1995) , we were able to generate permanently growing adherent cell lines. Since oncostatin M (OSM) in the medium primarily stimulates the growth of endothelial progenitor cells in AGM cultures (Mukouyama et al., 1998) and no hematopoietic cells are generated from the Runx1-null AGM region (Mukouyama et al., 2000) , we were able to use OSM-supplemented medium to obtain three independent Runx1-deficient AGM-derived endothelial-like cell lines, referred to as AEL (AGM-derived Endothelial-Like)-DR1 (Figure 1a) , AEL-DR2, and AEL-DR3. These cell lines were resistant to G418 (0.5 mg/ml) and ceased cell division when the culture temperature was shifted to 39.51C, which suggests that the transformation was successful. As expected, AEL-DR1 cells lacked mRNA expression of Runx1 but produced mRNA of its binding partner CBFb (Figure 1b) .
We next characterized the phenotype of the AEL-DR1 cells by fluorescence-activated cell sorting (FACS) (Figure 1c and d) . AEL-DR1 cells were positive for Sca-1 and podocalyxin-like protein 1 (PCLP1), weakly positive for Flk1, but negative for PECAM1, VEcadherin, CD34, c-Kit, Mac-1, and CD45 ( Figure 1c , data not shown). Also, as shown in Figure 1c , AEL-DR1 cells bound an early endothelial marker, lectin BSI-B4 (Bandeiraea simplicifolia isolectin B4) (Coffin et al., 1991) , and they incorporated acetylated low-density lipoprotein labeled with dioctadecyl-tetramethylindocarbocyanine perchlorate (DiI-AcLDL), which is a specific property of endothelial cells (Voyta et al., 1984) . The AEL-DR2 and AEL-DR3 cell lines exhibited similar phenotypes (data not shown). These FACS profiles resemble those of the PCLP1 þ CD45 -endothelial-like cells grown in the primary culture of AGM region (Hara et al., 1999) . AEL-DR1 cells transfected Before examining the function of Runx1 in the newly established AEL-DR1 cells, we confirmed that exogenously introduced Runx1 protein functions as a transcriptional activator in these cells, using the authentic Runx luciferase reporter construct, pCCP1-Luc (a kind gift from Dr I Kitabayashi) (Kitabayashi et al., 2001) . AEL-DR1 cells transfected with a Runx1 cDNA in pMY vector (a gift from Dr T Kitamura) expressed the mRNA for Runx1 (Figure 1b ) and exhibited a luciferase activity when cotransfected with pCCP1-Luc (data not shown).
To search for downstream effectors of Runx-1, we introduced the pLRT-Runx1 vector, which contains Runx1 cDNA under the control of the doxycycline (Dox)-inducible promoter (Figure 2a ) (Watsuji et al., 1997) , into AEL-DR1 cells by retroviral infection. The infected cells were selected based on blasticidin S resistance and several cell clones were isolated. We selected the clone AEL-DR1/LRT-Runx1 because it showed the lowest background and the highest inducibility by Dox. At 24 h after Dox was added to the culture medium, Runx1 mRNA and protein were detected in the AEL-DR1/LRT-Runx1 cells (Figure 2b and c). We took advantage of this inducible expression system of Runx1 to identify, by RDA, those genes whose expression is altered by introduction of Runx1 in AEL-DR1 cells. Since there was a low level of leaky Runx1 expression in AEL-DR1/LRT-Runx1 cells, we chose to compare untransfected AEL-DR1 cells and Dox-stimulated AEL-DR1/LRT-Runx1 cells as the tracer and the driver of the RDA, respectively. We isolated several candidate cDNA fragments and subsequent Northern blot analyses revealed that one gene exhibited a clear downregulation in Dox-stimulated AEL-DR1/LRTRunx1 cells. Its sequence was identical to that of mouse IGFBP-3 cDNA (GenBank Accession number X81581).
Runx1-induced repression of IGFBP-3 mRNA in AEL-DR1 cells
We quantitatively analysed the mRNA expression of IGFBP-3 and Runx1 in AEL-DR1/LRT-Runx1 cells at various time points after Dox addition. As shown in Figure 2b , Runx1 mRNA levels gradually increased in response to Dox-mediated transcriptional activation, while the mRNA levels for IGFBP-3 gradually decreased, thus showing an inverse correlation. Incubation with Dox did not nonspecifically attenuate transcription in AEL-DR1/LRT-Runx1 cells because the levels of glyceraldehyde 3-phosphate dehydrogenase (G3PDH) mRNA were unchanged ( Figure 2b ). The addition of Dox to untransfected AEL-DR1 cells did not affect IGFBP-3 mRNA levels (data not shown). Hence, the repression of IGFBP-3 mRNA is dependent on Runx1 expression, mediated by the pLRT-Runx1 construct.
To exclude the possibility that the above observation is an artifact induced by the retrovirus vector, we constructed a recombinant adenovirus carrying Runx1 under the cytomegalovirus promoter. The AEL-DR1, 2, and 3 cell lines were infected with the adenovirus encoding Runx1 and the total RNAs were extracted Total cell lysates prepared from AEL-DR1/LRT-Runx1 cells before and after the addition of Dox for 24 h were subjected to Western blot analysis by using antiRunx1 antibody. For the IGFBP-3, IGFBP-6 blotting, concentrated conditioned media harvested from 2-day cultured AEL-DR1/LRT-Runx1 cells in the presence or absence of Dox were used. (d) Suppression of the IGFBP-3 mRNA expression by adenoviral introduction of Runx1. Three independent Runx1-deficient cell lines (AEL-DR1, 2, 3) were infected with the recombinant adenovirus carrying Runx1 cDNA for 2 days. Total RNA from each of the cell lines, with or without adenovirus challenge, was subjected to Northern blot analysis. (e) Upregulation of IGFBP-3 mRNA in Runx1-deficient mouse embryos. Single AGM regions from Runx1-null embryos and a wild-type embryo were subjected to RT-PCR analysis. The ethidium bromide-staining patterns after PCR are shown. G3PDH was used to verify the equivalent quantities of the cDNA templates Runx1 promotes angiogenesis by suppressing IGFBP-3 K Iwatsuki et al from each culture 48 h after infection. Northern blot analyses of the AEL-DR1-3 cells before and after the infection revealed that the expression of Runx1and IGFBP-3 was inversely correlated, as seen in the retroviral transfection experiments (Figure 2d ). Visualization of total RNA by ethidium bromide staining after electrophoresis excluded the possibility that the RNAs were degraded by the adenovirus infection. Infection with an empty adenovirus did not alter IGFBP-3 expression in AEL-DR1-3 cells (data not shown). Thus, the retrovirus-and adenovirus-mediated Runx1 transfer experiments demonstrate that the expression of IGFBP-3 mRNA in AEL-DR1-3 cells is repressed by Runx1. In consistent with these observations, an amount of IGFBP-3 mRNA in Runx1(À/À) AGM regions was higher than that of wild-type AGM region ( Figure 2e ).
In mammals, the IGFBP family contains six related genes (IGFBP-1 to IGFBP-6). Thus, we examined their expression in AEL-DR1/LRT-Runx1 cells with or without Dox stimulation. Among the six family members, the mRNAs for IGFBP-3 and IGFBP-6 were detectable by Northern hybridization in the AEL-DR1/LRTRunx1 cells (data not shown). We next examined the protein expression level of IGFBP-3 and IGFBP-6 by Western blot analysis. Since these proteins are abundantly present in fetal calf serum, we cultured AEL-DR1/LRT-Runx1 cells with or without Dox in serum-free medium and whole secreted proteins in the supernatant were analysed. As shown in Figure 2c , production of IGFBP-3 protein was decreased, while that of IGFBP-6 was unaffected. Quantification of the band density using NIH Image software revealed that the amount of IGFBP-3 protein in the Dox-stimulated conditioned medium was 47.7% of that in the Doxuntreated sample. In this particular experiment, the estimated concentrations of IGFBP-3 and IGFBP-6 in the culture media at harvest were 48.6 ng/ml (IGFBP3, ÀDox), 23.1 ng/ml (IGFBP-3, þ Dox), 37.4 ng/ml (IGFBP-6, ÀDox), and 38.0 ng/ml (IGFBP-6, þ Dox), respectively. These data indicate that expression of IGFBP-3 protein, but not IGFBP-6 protein, is downregulated by Runx1.
Binding and repressor activity of Runx1 protein to a promoter region of the mouse IGFBP-3 gene Based on the genomic sequence (Accession number AL607124), we found two potential Runx-binding sites, which fit the reported consensus sequence (5 Wang and Speck, 1992; Meyers et al., 1993) and two sites which only differ from the consensus sequence by one base, À1 to À700 base pairs (bps) upstream of the mouse IGFBP-3 gene. To determine whether Runx1 binds to any of these DNA regions, we performed an electrophoretic mobility shift assay (EMSA). When we used a double-stranded oligonucleotide corresponding to Site 1 (Figure 3a , Table 1 ), a retarded band was observed (Figure 3b, arrow) . This band was competed out by an excess amount of the cold oligonucleotide but not by a mutated oligonucleotide. Furthermore, the band position was supershifted by the anti-Runx1 antibody in the reaction mixture (Figure 3b , open arrowhead). In contrast, similar bands were not observed with oligonucleotides for Site 2 or Sites 3,4 under the same experimental conditions.
We next examined whether Runx1 represses the promoter activity of mouse IGFBP-3 gene by reporter assays. When the IGFBP-3 promoter region of À249 to þ 29 was placed upstream of the luciferase cDNA, approximately 25% reduction of transcriptional activity was observed in AEL-DR1/LRT-Runx1 cells by Dox treatment (Figure 4 ). On the other hand, the shorter promoter region of À228 to þ 29, which is devoid of the Runx1-binding site, did not respond to Dox treatment for the reporter assay in AEL-DR1/ LRT-Runx1 cells. AEL-DR1 cells without the Runx1 vector exhibited no differences by the Dox addition in both reporter constructs, ruling out the side effect of Dox to the basal transcriptional activity. Therefore, we conclude that a protein complex containing Runx1 primarily interacts with Site 1, the most proximal Runx1-binding site of the mouse IGFBP-3 gene, and repress its transcription in AEL-DR1/LRTRunx1 cells. (Figure 5b ). In addition, (Figure 5a and b) . This inhibitory effect of IGFBP-3 was dose-dependent ( Figure 5d ). However, IGFBP-6 did not inhibit the in vitro angiogenesis of Dox-stimulated AEL-DR1/LRTRunx1 cells (Figure 5d ), suggesting that the inhibition is specific to IGFBP-3. IGFBP-3 was inhibitory to the growth of AEL-DR1 and AEL-DR1/LRT-Runx1 cells irrespective of the Dox treatment (Figure 5c ).
Discussion
The major aim of this study was to clarify whether Runx1 is directly involved in the differentiation and maturation of embryonic endothelial cells. To eliminate any interaction with hematopoietic cells, which are known to derive from hemogenic endothelial cells (reviewed by Keller et al., 1999) , we first immortalized endothelial progenitor cells in primary cultures of Runx1-null AGM region cells using a temperaturesensitive SV40T antigen. The newly established cells lines, AEL-DR1-3, phenotypically resembled the endothelial progenitor cell fraction in the AGM region since they expressed a hemangioblast marker PCLP1 and incorporated DiI-AcLDL, but are negative for mature endothelial antigens such as PECAM1 and VEcadherin (Hara et al., 1999) . Upon the conditional expression of Runx1 in AEL-DR1 cells, expression of VE-cadherin was initiated (Figure 1d ) and the vascular network formation activity of the cells was greatly enhanced (Figure 5a ), suggesting that endothelial differentiation and maturation were induced by Runx1.
The functional relevance of Runx1 in angiogenesis has been suggested by two previous reports. Takakura et al. (2000) pointed out the reduction in branching of small vessels in the Runx1-null mouse embryo and in explant cultures of its para-aortic splenchnopleural region. Although the defect in the explant culture assay was rescued by the addition of HSCs or angiopoietin-1, the relatively lower angiogenic activity of the Runx-1-deficient endothelial cells themselves, as was observed in AEL-DR1 cells, may contribute to the in vivo defect in the Runx1-null embryo. On the other hand, inhibition of the growth and tube-forming activity of MSS31 endothelial cells by CBFb-MYH11 (Namba et al., 2000) has suggested a direct involvement of Runx1 in angiogenesis. In this cell line, VEGF and basic fibroblast growth factor (bFGF) augmented the expression of Runx1 and its DNA-binding activity. Rescue of the impaired in vitro angiogenesis of AEL-DR1 cells by Runx1 in this study provides conclusive evidence for the involvement of Runx1 in angiogenesis. Taken together with recent findings showing that Runx2 is required for the in vitro differentiation of HBME-1 endothelial cells and positively regulates the expression of angiogenesisrelated genes such as VEGF, urokinase-type plasminogen activator, and membrane type 1 matrix metalloproteinase (Sun et al., 2001; Zelzer et al., 2001) , Runx1 and Runx2 must play critical roles, independently or in combination, in angiogenesis both in embryos and adults.
We screened for cDNAs that are either up-or downregulated in the AEL-DR1/LRT-Runx1 cells upon the restored expression of Runx1. We found that the amount of IGFBP-3 mRNA is decreased by the expression of Runx1 (Figure 2b ). We also noticed that several other mRNA species were slightly decreased in Dox-induced AEL-DR1/LRT-Runx1 cells (KI, TH, unpublished) . We have previously reported that the mRNAs encoding c-fms, c-vav, and PU.1 are not expressed in the AGM region of Runx1-null mice (Okada et al., 1998) . In the AEL-DR1/LRT-Runx1 cells, however, the induction of Runx1 did not alter the expression level of these genes. As hematopoiesis does not occur in the Runx1-null AGM region (Okuda et al., 1996; Wang et al., 1996) , it is likely that the missing expression of c-fms, c-vav, and PU.1 in the Runx1-null mice is not a direct outcome of the Runx1 deficiency, but rather due to the lack of hematopoietic cells.
We confirmed that IGFBP-3 mRNA is specifically suppressed by the enforced expression of Runx1 in AEL-DR1 cells by employing two separate experimental systems. First, in the Dox-inducible system, we observed that suppression of IGFBP-3 expression started as early as 4-8 h after Runx1 mRNA was detected (Figure 2b) . Second, infection of the three independent AEL-DR cell lines with an adenovirus carrying Runx1 cDNA leads to the downregulation of IGFBP-3 mRNA (Figure 2d ). Inverse correlation between amounts of Runx1 and IGFBP-3 mRNAs was also observed in intact AGM regions of mouse embryos (Figure 2e) . Downregulation of IGFBP-3 mRNA by Runx1 appeared to occur at the transcriptional level based on the EMSA and reporter assay data showing that Runx1 bound to the most proximal Runx-consensus-binding site in the upstream region of the mouse IGFBP-3 gene and repress its transcriptional activity (Figures 3 and 4) . In mammals, the Runx proteins have been shown to suppress the transcription of differentiation-related genes via conserved C terminal VWRPY domains in a Groucho/TLEdependent manner (Levanon et al., 1998; Javed et al., 2000) . Recently, it was shown that Runx1 and Runx2 repress expression of a cyclin-dependent kinase inhibitor p21 Waf1/Cip1 by interacting with other corepressors (Lutterbach et al., 2000; Westendorf et al., 2002) . A very recent report also revealed that tissue inhibitor of metalloproteinase 1 gene is negatively regulated by Runx1 (Bertrand-Philippe et al., 2004) . In this study, we demonstrated the repression of IGFBP-3 mRNA in the endothelial progenitor cell line by Runx1.
IGFBP-3 belongs to the IGFBP family, which is composed of six structurally related members (for a review, see Jones and Clemmons, 1995; Hwa et al., 1999) . Among them, IGFBP-3 is known to be the major reservoir of IGF-I and IGF-II and it preserves them from proteolytic degradation. It is also reported that IGFBP-3 can inhibit cell growth or induce apoptosis in an IGF-independent fashion. Two reports have shown that IGFBP-3 inhibited the growth of bovine aortic endothelial cells (Delafontaine et al., 1996) and the IGF/ VEGF-induced proliferation of human umbilical vein endothelial cells (Franklin et al., 2003) . In this study, we demonstrated that IGFBP-3 is inhibitory for both proliferation and in vitro angiogenesis of the mouse endothelial progenitor cell line AEL-DR1/LRT-Runx1 (Figure 5a-c) . This effect is apparently independent from the mild growth inhibition by IGFBP-3, since the cells were inoculated on matrigel for only a half-day. Moreover, IGFBP-6 was not inhibitory for in vitro angiogenesis of AEL-DR1/LRT-Runx1 cells, even at a higher concentration (Figure 5d ), suggesting an IGFBP-3-specific biological activity. The reasons why exogenously added IGFBP-3 did not completely neutralize the network-forming activity of AEL-DR1/LRT-Runx1 cells could be as follows. First, other Runx1 effecter molecules could contribute to the full angiogenic activity. It has been suggested that expression of angiopoietin-1 is positively regulated by Runx1 in the MSS31 endothelial cells (Namba et al., 2000) . Second, IGFBP-3 may act inside the cell, as in the case of IGFBP-3 binding to the nuclear receptor in human breast cancer cells (Gucev et al., 1996) .
It has been reported that VEGF and transforming growth factor b1 downregulate the expression of IGFBP-3 in aortic endothelial cells (Erondu et al., 1996; Dahlfors and Arnqvist, 2000) , while IGF, tumor necrosis factor a, and interleukin-1 upregulate it in endothelial cells or articular chondrocytes (Olney et al., 1995; Erondu et al., 1996) . Thus, IGFBP-3 may be a downstream effecter for many growth regulatory cytokines and its transcription must be regulated differently depending on the cell type. In regard to the transcriptional activation of the IGFBP-3 gene, an Sp1/AP2-binding site located between À98 and À75 bps relative to the transcription start site of the human IGFBP-3 has been shown to be important (Choi et al., 2002) . There is an Sp1/AP2 element in the corresponding genomic region, À99 to À86 bps, of the mouse IGFBP-3 gene. The Runx1-binding site 1 is located further upstream between À240 and À234 bps (Figure 3a) . Several potential Runx1-binding sequences were also found in the upstream regions of human, bovine, and porcine IGFBP-3 genes (Cubbage et al., 1990; Erondu et al., 1997; Ongeri et al., 2004) , although repression of IGFBP-3 by Runx1 in these species remains to be determined.
IGFBP-3 is known to be overexpressed during the angiogenic phase of the corpus luteum in rats, primates, and humans (Erickson et al., 1993; Fraser et al., 1998; Fraser et al., 2000) . Other reports also indicate that IGFBP-3 mRNA is more abundantly expressed in hypoxia-associated inflammatory angiogenesis (Tucci et al., 1998; Lee et al., 1999) and tumor endothelial cells (Schmid et al., 2003) . However, the physiological roles of IGFBP-3 in adult angiogenesis have not been elucidated. It is tempting to examine the expression and function of Runx1 and IGFBP-3 in both physiological and disease-associated angiogenesis in adults.
In conclusion, we have demonstrated for the first time that Runx1 is required for in vitro angiogenic activity through its suppression of IGFBP-3 expression. IGFBP-3 specifically inhibits Runx1-mediated vascular network formation by endothelial progenitor cells. In addition to inducing the development of HSCs, which provide angiopoietin-1, we propose that Runx1 plays another important role in embryonic angiogenesis by regulating IGFBP-3 production. Our new cell system will be useful for further experiments to explore the structurefunction relationship of Runx proteins in the regulation of other downstream effecter molecules in angiogenesis.
Materials and methods
Generation of Runx1-null endothelial progenitor cell lines
Runx1 knockout mice and the genotyping procedure have been described previously (Okada et al., 1998) . Primary culture of AGM-derived cells and the retrovirus infection that immortalized them were based on published methods (Lee et al., 1995; Mukouyama et al., 1998) . In brief, cells from an AGM region of Runx1-null embryo at 11.5 dpc were cultured at 371C in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St Louis, MO, USA) supplemented with 15% fetal calf serum (Hyclone, Logan UT, USA), murine stem cell factor (100 ng/ ml) (provided by Kirin Brewery, Takasaki, Japan), human bFGF (1 ng/ml) (Invitrogen, Carlsbad, CA, USA), and murine OSM (10 ng/ml) (R&D systems, Minneapolis, MN, USA). The following day, the adherent cells were infected for 24 h in the presence of polybrene (8 mg/ml, Sigma) with a recombinant retrovirus producing a temperature-sensitive form of the SV40 large T antigen. The retrovirus was produced as previously described by using the PLAT-E packaging cell line (Morita et al., 2000) and the pMESVts retrovirus vector (Lee et al., 1995) . The infected cells were allowed to grow for 2-3 weeks at 32.51C and three cell islands designated as AEL-DR1, 2, and 3 were isolated using penicillin cups. After 1 month of subculturing, all cytokines were removed from the growth medium and the cells were maintained at 32.51C. All animal and recombinant DNA experiments were preapproved by the appropriate institutional committees.
RT-PCR
First strand cDNAs were prepared from total RNA samples using SuperScript II reverse transcriptase (Invitrogen). The RT-PCR reactions were carried out as previously described at an annealing temperature of 601C by using the following sets of primers: 5 0 -CAACTTCCTCT GCTCCGTGCTACCC-3 0 and 5 0 -AAGGCAGTGGAGTGG TTCAAGGAGGC-3 0 , which amplifies 492 bps of Runx1; 5 0 -C GGACCAGAGGAGCAAGTTCGAG-3 0 and 5 0 -GGGTC TTGCTGTCTTCTTGCCAG-3 0 , which amplifies 530 bps of CBFb; and 5 0 -ACCACAGTCCATGCCATCAC-3 0 and 5 0 -TCCACCACCCTGTTGCTGTA-3 0 , which amplifies 450 bps of G3PDH.
FACS
The expression of cell surface antigens on AEL-DR1 cells was examined by flow cytometry using an EPICS-XL flow cytometer (Beckman-Coulter, Miami, FL, USA) as previously described . Monoclonal antibodies specific for Sca-1 (E13-161.7), Flk1 (Avas12a1), Mac-1 (M1/70), CD34 (RAM34), c-Kit (2B8), PECAM1 (MEC13.3), CD45 (30-F11), and phycoerythrin-conjugated streptavidin were purchased from BD Biosciences (San Jose, CA, USA). The biotinylated anti-PCLP1 antibody was described previously (Hara et al., 1999) (MBL, Nagoya, Japan). Anti-VEcadherin antibody was a kind gift from Dr S Nishikawa. Fluorescein isothiocyanate-conjugated anti-rat IgG antibody, biotinylated BSI-B4, and DiI-AcLDL were purchased from ICN Pharmaceuticals (Aurora, OH, USA), Vector Laboratories (Burlingame, CA, USA) and Biomedical Technologies (Stoughton, MA, USA), respectively.
Conditional expression of Runx1 cDNA and adenovirus production
For the conditional expression of Runx1, we inserted the coding region of mouse Runx1 cDNA (Bae et al., 1993) into the pLRT plasmid, which is the reverse-tetracycline-regulated retroviral vector (Watsuji et al., 1997) . The AEL-DR1 cell line was infected with the retrovirus carrying pLRT-Runx1 and subjected to selection with blasticidin S (10 mg/ml) (Wako, Osaka, Japan). Runx1 expression before and after the addition of Dox (1 mg/ml) (BD Biosciences) was examined by Northern blotting in several independent transfectant clones of AEL-DR1 cells. The recombinant adenovirus carrying Runx1 cDNA was generated by employing the AdEasy system (Stratagene, La Jolla, CA, USA). A high titer of adenovirus stock was prepared according to the manufacturer's instructions and used to infect AEL-DR1-3 cells.
Cloning of cDNAs whose expression is altered by Runx1
A pLRT-Runx1 transfectant clone of AEL-DR1 cells was treated with Dox for 24 h and subjected to poly(A) þ RNA extraction. As previously described , we performed RDA between this sample and the mRNA of the original AEL-DR1 cells to identify those mRNAs that are either upregulated or downregulated by Runx1. The candidate cDNA fragments were then sequenced and used for BLAST searching against the public database.
Northern and Western blot analyses
Northern blot hybridization was performed with Digoxygenin (DIG)-labeled cRNA probes as previously described (Iwatsuki et al., 2000) . Western blotting for Runx1 was carried out as described before using rabbit anti-Runx1 serum (1 : 1000 dilution) (Namba et al., 2000) . For the detection of IGFBP-3 and IGFBP-6, confluent AEL-DR1/LRT-Runx1 cells grown for 3 days at 32.51C in the presence or absence of Dox were cultured for 2 more days in serum-free DMEM. Conditioned media were concentrated by centrifugation in Microcon YM-10 (Millipore, Bedford, MA, USA) and subjected to electrophoresis on a 10% polyacrylamide gel in the presence of SDS under reducing conditions. Proteins transferred onto a polyvinylidene difluoride membrane (Millipore) were blocked by 5% skim milk (Difco, Detroit, MI, USA) and incubated for 1 h at RT with goat anti-IGFBP-3 or anti-IGFBP-6 antibody (Genzyme, Minneapolis, MN, USA). The membrane was stained with biotinylated rabbit anti-goat IgG antibody and horseradish peroxidase-conjugated streptavidin (Vector Laboratories). Immunoreacting bands were detected using the ECL-Plus reagent (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
EMSA AEL-DR1/LRT-Runx1 cells were cultured for 3 days at 32.51C in the presence of Dox. A cell lysate was prepared by the freeze-thaw method, as previously described (Namba et al., 2000) . Three double-stranded oligonucleotides were endlabelled with [g 32 P]ATP (Amersham Pharmacia Biotech) using T4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA). Sequences of the oligonucleotides used in this study are listed in Table 1 . The same amount of protein was incubated with the 32 P-labeled DNA probe (1 Â 10 4 count per min) and in 10 ml of 20 mM HEPES-KOH (pH 7.6), 50 mM KCl, 2 mM EDTA, 1 mM dithiothreitol (Sigma), 4% Ficoll (Sigma), and 1.5 mg of poly dI-dC (Amersham Pharmacia Biotech) for 30 min at room temperature in the presence or absence of an excess amount of competitor unlabeled oligonucleotide. In some samples, 1 ml of anti-Runx1 polyclonal antibody (Namba et al., 2000) was added and further incubated for 30 min at room temperature. Reacted samples were separated on a 6% DNA retardation polyacrylamide gel (Invitrogen) and exposed to a BAS cassette 2040 (Fujifilm, Tokyo, Japan) followed by analysis with a BAS-2500 phosphor imager and Image Gauge Version 3.2 (Fujifilm).
Reporter assay
Genomic DNA fragments (À228 to þ 29 and À249 to þ 29) of the mouse IGFBP-3 promoter region were PCR-amplified and cloned into a BglII/HindIII site of pGL3 basic vector (Promega, Madison, WI, USA). AEL-DR1 and AEL-DR1/ LRT-Runx1 cells were treated with or without Dox for 2 days and were cotransfected with the reporter construct and pRLCMVvector (Promega) by using Effectene transfection reagent (Qiagen, Hilden, Germany). Cells were lysed 48 h after transfection and analysed by Dual-Luciferase reporter assay system (Promega).
Matrigel and proliferation assays
AEL-DR1/LRT-Runx1 cells were cultured for 3 days at 32.51C in the presence or absence of Dox. Cells (1.5 Â 10 5 ) were resuspended in 1 ml of StemPro-34 SFM complete medium (Invitrogen) with or without Dox, recombinant mouse IGFBP-3 or IGFBP-6 (R&D Systems) and overlayed on a Biocoat matrigel basement membrane (BD Biosciences) in a six-well plate. After a 12-14 h incubation at 371C, the number of polygonal areas formed by vascular tube-like structures was counted under a microscope for each well. For the cell proliferation assay, AEL-DR1/LRT-Runx1 cells grown for 3 days at 32.51C in the presence or absence of Dox were inoculated in 0.1 ml of StemPro-34 medium with or without Dox or IGFBP-3 in 96-well plates at 10 4 per well. After 3 days of culture at 32.51C, 10 ml of Cell Counting Kit-8 (Wako) was added to each well and cells were incubated for an additional 4 h followed by spectrophotometrical measurement at 450 nm.
